QUANTUM DOT LABELED STEM CELLS FOR USE IN CARDIAC REPAIR
    2.
    发明申请
    QUANTUM DOT LABELED STEM CELLS FOR USE IN CARDIAC REPAIR 审中-公开
    量子标签干细胞用于心脏修复

    公开(公告)号:US20100158805A1

    公开(公告)日:2010-06-24

    申请号:US12532780

    申请日:2008-03-21

    摘要: The present invention provides methods and compositions relating to the labeling of target cells with quantum dots (QDs). Specifically, a delivery system is disclosed based on the use of negatively charged QDs for delivery of a tracking fluorescent signal into the cytosol of target cells via a passive endocytosis-mediated delivery process. In a specific embodiment of the invention the target cell is a stem cell, preferably a mesenchymal stem cell (MSC). Such labeled MSCs provide a means for tracking the distribution and fate of MSCs that have been administered to a subject to promote cardiac repair. The invention is based on the discovery that MSCs can be tracked in vitro for up to at least 6 weeks. Additionally, QDs delivered in vivo can be tracked for up to at least 8 weeks, thereby permitting for the first time, the complete 3-D reconstruction of the locations of all MSCs following administration into a host.

    摘要翻译: 本发明提供了关于用量子点(QD)标记靶细胞的方法和组合物。 具体地,基于使用带负电荷的量子点,通过被动内吞作用介导的递送过程将跟踪荧光信号传递到靶细胞的胞质溶胶中,公开了递送系统。 在本发明的具体实施方案中,靶细胞是干细胞,优选间充质干细胞(MSC)。 这些标记的MSC提供了跟踪已经施用于受试者以促进心脏修复的MSC的分布和命运的手段。 本发明基于这样的发现,MSC可以在体外追踪长达至少6周。 另外,在体内交付的量测数据可以跟踪至少8周,从而允许在管理到主机之后,所有MSC的位置的完整三维重构。

    Quantum dot labeled stem cells for use in providing pacemaker function
    3.
    发明申请
    Quantum dot labeled stem cells for use in providing pacemaker function 有权
    用于提供起搏器功能的量子点标记的干细胞

    公开(公告)号:US20090062876A1

    公开(公告)日:2009-03-05

    申请号:US12077970

    申请日:2008-03-21

    摘要: The present invention provides methods and compositions relating to the labeling of target cells with nanometer scale fluorescent semiconductors referred to as quantum dots (QDs). Specifically, a delivery system is disclosed based on the use of negatively charged QDs for delivery of a tracking fluorescent signal into the cytosol of target cells via a passive endocytosis-mediated delivery process. In a specific embodiment of the invention the target cell is a stem cell, preferably a mesenchymal stem cell (MSC). Such labeled MSCs provide a means for tracking the distribution and fate of MSCs that have been genetically engineered to express, for example, a hyperpolarization-activated cyclic nucleotide-gated (“HCN”) channel and administered to a subject to create a biological pacemaker. The invention is based on the discovery that MSCs can be tracked in vitro for up to at least 6 weeks. Additionally, QDs delivered in vivo can be tracked for up to at least 8 weeks, thereby permitting for the first time, the complete 3-D reconstruction of the locations of all MSCs following administration into a host.

    摘要翻译: 本发明提供了与称为量子点(QD)的纳米尺度荧光半导体标记靶细胞有关的方法和组合物。 具体地,基于使用带负电荷的量子点,通过被动内吞作用介导的递送过程将跟踪荧光信号传递到靶细胞的胞质溶胶中,公开了递送系统。 在本发明的具体实施方案中,靶细胞是干细胞,优选间充质干细胞(MSC)。 这种标记的MSC提供了用于跟踪已经被遗传工程化以表达例如超极化激活的环核苷酸门控(“HCN”)信道并且施用于受试者以创建生物起搏器的MSC的分布和命运的手段。 本发明基于这样的发现,MSC可以在体外追踪长达至少6周。 另外,在体内交付的量测数据可以跟踪至少8周,从而允许在管理到主机之后,所有MSC的位置的完整三维重构。

    COMPOSITIONS OF LATE PASSAGE MESENCHYMAL STEM CELLS (MSCS)
    6.
    发明申请
    COMPOSITIONS OF LATE PASSAGE MESENCHYMAL STEM CELLS (MSCS) 审中-公开
    最近一次通过的骨髓间充质干细胞(MSCS)

    公开(公告)号:US20100047216A1

    公开(公告)日:2010-02-25

    申请号:US12374027

    申请日:2007-07-20

    摘要: The present invention provides methods and compositions relating to the use of late passage mesenchymal stem cells (MSCs) for treatment of cardiac disorders. Such late passage MSCs may be administered to the myocardium of a subject for induction of native cardiomyoctye proliferation and repair of cardiac tissue. Additionally, the late passage MSCs may be genetically engineered to express a gene encoding a physiologically active protein of interest and/or may be incorporated with small molecules for delivery to adjacent target cells through gap junctions. The late passage MSCs of the invention may be used to provide biological pacemaker activity and/or provide a bypass bridge in the heart of a subject afflicted with a cardiac rhythm disorder. The biological pacemaker activity and/or bypass bridge may be provided to the subject either alone or in tandem with an electronic pacemaker.

    摘要翻译: 本发明提供了与晚期传代间充质干细胞(MSC)用于治疗心脏病的方法和组合物。 这种晚期传代MSC可以施用于受试者的心肌,以诱导天然心肌细胞增殖和心脏组织的修复。 另外,晚期传代的MSC可被遗传工程化以表达编码目标生理活性蛋白质的基因和/或可与小分子结合,以通过间隙连接递送至相邻靶细胞。 本发明的晚期传代MSC可用于提供生物起搏器活动和/或在患有心律失常的受试者的心脏中提供旁路桥。 生物起搏器活动和/或旁通桥可以单独提供或与电子起搏器串联提供给受试者。

    Quantum dot labeled stem cells for use in providing pacemaker function
    8.
    发明授权
    Quantum dot labeled stem cells for use in providing pacemaker function 有权
    用于提供起搏器功能的量子点标记的干细胞

    公开(公告)号:US08170665B2

    公开(公告)日:2012-05-01

    申请号:US12077970

    申请日:2008-03-21

    IPC分类号: A61N1/00

    摘要: The present invention provides methods and compositions relating to the labeling of target cells with nanometer scale fluorescent semiconductors referred to as quantum dots (QDs). Specifically, a delivery system is disclosed based on the use of negatively charged QDs for delivery of a tracking fluorescent signal into the cytosol of target cells via a passive endocytosis-mediated delivery process. In a specific embodiment of the invention the target cell is a stem cell, preferably a mesenchymal stem cell (MSC). Such labeled MSCs provide a means for tracking the distribution and fate of MSCs that have been genetically engineered to express, for example, a hyperpolarization-activated cyclic nucleotide-gated (“HCN”) channel and administered to a subject to create a biological pacemaker. The invention is based on the discovery that MSCs can be tracked in vitro for up to at least 6 weeks. Additionally, QDs delivered in vivo can be tracked for up to at least 8 weeks, thereby permitting for the first time, the complete 3-D reconstruction of the locations of all MSCs following administration into a host.

    摘要翻译: 本发明提供了与称为量子点(QD)的纳米尺度荧光半导体标记靶细胞有关的方法和组合物。 具体地,基于使用带负电荷的量子点,通过被动内吞作用介导的递送过程将跟踪荧光信号传递到靶细胞的胞质溶胶中,公开了递送系统。 在本发明的具体实施方案中,靶细胞是干细胞,优选间充质干细胞(MSC)。 这种标记的MSC提供了用于跟踪已经被遗传工程化以表达例如超极化激活的环核苷酸门控(“HCN”)信道并且施用于受试者以创建生物起搏器的MSC的分布和命运的手段。 本发明基于这样的发现,MSC可以在体外追踪长达至少6周。 另外,在体内交付的量测数据可以跟踪至少8周,从而允许在管理到主机之后,所有MSC的位置的完整三维重构。

    Methods for Assisting Recovery of Damaged Brain and Spinal Cord and Treating Various Diseases Using Arrays of X-Ray Microplanar Beams
    10.
    发明申请
    Methods for Assisting Recovery of Damaged Brain and Spinal Cord and Treating Various Diseases Using Arrays of X-Ray Microplanar Beams 有权
    使用X射线微平面光束阵列辅助损伤脑脊髓的恢复和治疗各种疾病的方法

    公开(公告)号:US20080292052A1

    公开(公告)日:2008-11-27

    申请号:US11884158

    申请日:2006-02-10

    IPC分类号: A61N5/10

    摘要: A method of assisting recovery of an injury site of the central nervous system (CNS) or treating a disease includes providing a therapeutic dose of X-ray radiation to a target volume through an array of parallel microplanar beams. The dose to treat CNS injury temporarily removes regeneration inhibitors from the irradiated site. Substantially unirradiated cells surviving between beams migrate to the in-beam portion and assist recovery. The dose may be staggered in fractions over sessions using angle-variable intersecting microbeam arrays (AVIMA). Additional doses are administered by varying the orientation of the beams. The method is enhanced by injecting stem cells into the injury site. One array or the AVIMA method is applied to ablate selected cells in a target volume associated with disease for palliative or curative effect. Atrial fibrillation is treated by irradiating the atrial wall to destroy myocardial cells while continuously rotating the subject.

    摘要翻译: 辅助恢复中枢神经系统(CNS)的损伤部位或治疗疾病的方法包括通过平行微平面光束阵列向目标体积提供治疗剂量的X射线辐射。 治疗CNS损伤的剂量暂时从照射部位移除再生抑制剂。 在梁之间存活的基本未照射的细胞迁移到入射梁部分并辅助恢复。 剂量可以使用角度可变的相交微束阵列(AVIMA)在会话上以分数交错。 通过改变梁的取向来施加额外的剂量。 通过将干细胞注射到损伤部位来增强该方法。 应用一个阵列或AVIMA方法来消融与疾病相关的目标体内的选择的细胞用于姑息治疗或治疗效果。 通过照射心房壁来破坏心肌细胞,同时持续旋转受试者来治疗房颤。